Adalimumab

Where the papers sit

22 papers from the last 6 months study adalimumab directly · updated from PubMed 7 Oct 2026

• Anti-TNF Therapy in Inflammation

  Anti-TNF treatment is moving toward pharmacokinetic guidance, immunogenicity control and more flexible delivery across inflammatory diseases. Inflammatory bowel disease work emphasizes population models, biosimilar switching and comparative safety, while methotrexate is examined for limiting adalimumab immunogenicity. Other studies explore macrophage reprogramming and polyelectrolyte delivery in immune-mediated disease. Evidence remains disease-specific, with uncertain effects on long-term outcomes and optimal dosing.

  8 papers · 36.4%

• Real-World Anti-TNF Outcomes

  Real-world anti-TNF care is moving from initial response toward durability, long-term safety and practical biosimilar use. Prospective and cohort studies assess adalimumab in pyoderma gangrenosum, hidradenitis suppurativa and granulomatous lobular mastitis, including treatment-naive patients. Switching studies track transitions to biosimilars and switch-back behavior, while rheumatoid arthritis data provide a long-term comparison with upadacitinib. Predictors of persistence and reliable comparative effectiveness remain unsettled.

  6 papers · 27.3%

• Biologic Therapy in Psoriasis

  Biologic selection is moving toward comparative safety and pharmacokinetic personalization in psoriasis. Cohort and target-trial analyses compare serious infection risk across secukinumab, ixekizumab, etanercept and other biologics. Pediatric experience broadens the evidence beyond adults, while therapeutic drug monitoring tests whether adalimumab exposure can guide dosing. Direct comparative effectiveness and clinically useful drug-level thresholds remain open questions.

  4 papers · 18.2%

• Therapeutic Antibody Engineering

  Therapeutic antibody development is shifting toward conditional activation, sustained dosing and tighter control of molecular quality. Masking domains are being designed to restrict activity until antibodies reach the intended context, while cell-based platforms aim to provide yearly, dose-tunable delivery. Single-protein measurements address size and charge heterogeneity, and Fab studies focus on proline-dependent stability and aggregation. The shared goal is to improve antibody exposure without sacrificing manufacturability or structural integrity.

  4 papers · 18.2%